Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.
[esophageal squamous cell carcinoma]
microRNA-
133
a
(
miR-
133
a
)
and
miR-
133
b
,
located
on
chromosome
18
in
the
same
bicistronic
unit
,
have
been
commonly
identified
as
being
downregulated
in
esophageal
squamous
cell
carcinoma
(
ESCC
)
.
The
aim
of
this
study
was
to
investigate
the
correlation
of
miR-
133
a
/
b
expression
with
efficacy
of
paclitaxel-based
chemotherapy
and
clinical
outcome
of
ESCC
patients
.
miR-
133
a
expression
and
miR-
133
b
expression
were
examined
in
100
newly
diagnosed
ESCC
patients
prior
to
treatment
by
quantitative
real-time
PCR
.
Then
,
the
patients
received
four
cycles
of
paclitaxel-based
chemotherapy
,
the
short
-term
treatment
efficacy
was
evaluated
,
and
a
3
-
year
follow-up
was
performed
.
Expression
levels
of
miR-
133
a
and
miR-
133
b
were
both
significantly
lower
in
ESCC
tissues
compared
to
adjacent
noncancerous
tissues
(
both
P
<
0
.
001
)
.
In
addition
,
combined
miR-
133
a
/
b
downregulation
was
found
to
be
closely
correlated
with
advanced
tumor
stage
(
P
=
0
.
02
)
and
poor
differentiation
(
P
=
0
.
01
)
.
Moreover
,
the
response
rate
of
ESCC
patients
to
paclitaxel-based
chemotherapy
was
significantly
higher
in
combined
miR-
133
a
/
b
downregulation
group
compared
with
other
groups
(
P
=
0
.
02
)
.
Furthermore
,
univariate
and
multivariate
Cox
analyses
revealed
that
tumor
stage
and
combined
expression
of
miR-
133
a
/
b
were
independent
prognosis
factors
in
ESCC
patients
.
Our
data
offer
the
convincing
evidence
that
combined
expression
of
miR-
133
a
and
miR-
133
b
may
predict
chemosensitivity
of
patients
with
ESCC
undergoing
paclitaxel-based
chemotherapy
,
implying
its
importance
in
applying
'
personalized
cancer
medicine
'
in
the
clinical
treatment
of
ESCC
.
We
also
identified
combined
expression
of
miR-
133
a
and
miR-
133
b
as
an
effective
prognostic
marker
of
this
malignancy
.